Global Hepatitis B Vaccine (Recombinant) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hepatitis B Vaccine (Recombinant) Market Research Report 2024
Hepatitis B vaccine is a vaccine that prevents hepatitis B.
According to Mr Accuracy reports’s new survey, global Hepatitis B Vaccine (Recombinant) market is projected to reach US$ 1271 million in 2034, increasing from US$ 1021.8 million in 2022, with the CAGR of 3.1% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hepatitis B Vaccine (Recombinant) market research.
In the last several years, Global market of Hepatitis B vaccine developed smoothly, with an average growth rate of -0.32%.
The classification of Hepatitis B vaccine includes Yeast Derived, CHO Derived, and the sales proportion of Yeast Derived in 2019 is about 97%. Hepatitis B vaccine is widely used for Children and Adult. About 84% of Hepatitis B vaccine is used for Children.
Asia-Pacific is the largest consumption place, with a consumption market share nearly 50% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of nearly 31%.
Market competition is intense. GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hepatitis B Vaccine (Recombinant) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
GSK
Merck
Sanofi Pasteur
Dynavax Technologies
LG Life Sciences
KM Biologics
Shenzhen Kangtai Biological Products
Serum Institute
Segment by Type
10mcg/0.5ml
10mcg/ml
Newborn
Adult
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hepatitis B Vaccine (Recombinant) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Hepatitis B Vaccine (Recombinant) market is projected to reach US$ 1271 million in 2034, increasing from US$ 1021.8 million in 2022, with the CAGR of 3.1% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hepatitis B Vaccine (Recombinant) market research.
In the last several years, Global market of Hepatitis B vaccine developed smoothly, with an average growth rate of -0.32%.
The classification of Hepatitis B vaccine includes Yeast Derived, CHO Derived, and the sales proportion of Yeast Derived in 2019 is about 97%. Hepatitis B vaccine is widely used for Children and Adult. About 84% of Hepatitis B vaccine is used for Children.
Asia-Pacific is the largest consumption place, with a consumption market share nearly 50% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of nearly 31%.
Market competition is intense. GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hepatitis B Vaccine (Recombinant) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GSK
Merck
Sanofi Pasteur
Dynavax Technologies
LG Life Sciences
KM Biologics
Shenzhen Kangtai Biological Products
Serum Institute
Segment by Type
10mcg/0.5ml
10mcg/ml
Segment by Application
Newborn
Adult
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hepatitis B Vaccine (Recombinant) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices